MDL 27324

Drug Profile

MDL 27324

Latest Information Update: 15 Sep 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aventis
  • Class Anti-inflammatories
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Emphysema

Most Recent Events

  • 10 Jul 2000 Discontinued - Preclinical for Adult respiratory distress syndrome in USA (unspecified route)
  • 10 Jul 2000 Discontinued for Emphysema in USA (unspecified route)
  • 10 Jul 1996 No-Development-Reported for Adult respiratory distress syndrome in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top